90 related articles for article (PubMed ID: 17592825)
1. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Risebrough NA; Verma S; Trudeau M; Mittmann N
Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden JP; Alvarez I; Bertelli G; Coates AS; Coleman R; Fallowfield L; Jassem J; Jones S; Kilburn L; Lønning PE; Ortmann O; Snowdon C; van de Velde C; Andersen J; Del Mastro L; Dodwell D; Holmberg S; Nicholas H; Paridaens R; Bliss JM; Coombes RC
J Clin Oncol; 2017 Aug; 35(22):2507-2514. PubMed ID: 28467729
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Speirs V; Viale G; Mousa K; Palmieri C; Reed SN; Nicholas H; Cheang M; Jassem J; Lønning PE; Kalaitzaki E; van de Velde CJH; Rasmussen BB; Verhoeven DM; Shaaban AM; Bartlett JMS; Bliss JM; Coombes RC;
Ann Oncol; 2015 Sep; 26(9):1890-1897. PubMed ID: 26002610
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
Szijgyarto Z; Flach KD; Opdam M; Palmieri C; Linn SC; Wesseling J; Ali S; Bliss JM; Cheang MCU; Zwart W; Coombes RC
Breast Cancer Res Treat; 2019 May; 175(1):149-163. PubMed ID: 30680659
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Cheang MCU; Bliss JM; Viale G; Speirs V; Palmieri C; Shaaban A; Lønning PE; Morden J; Porta N; Jassem J; van De Velde CJ; Rasmussen BB; Verhoeven D; Bartlett JMS; Coombes RC;
Breast Cancer Res Treat; 2018 Feb; 168(1):169-178. PubMed ID: 29177605
[TBL] [Abstract][Full Text] [Related]
7. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.
Markopoulos C; Dafni U; Misitzis J; Zobolas V; Tzoracoleftherakis E; Koukouras D; Xepapadakis G; Papadiamantis J; Venizelos B; Antonopoulou Z; Gogas H
Breast Cancer Res; 2009; 11(3):R35. PubMed ID: 19531217
[TBL] [Abstract][Full Text] [Related]
8. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Fontein DBY; Houtsma D; Hille ETM; Seynaeve C; Putter H; Meershoek-Klein Kranenbarg E; Guchelaar HJ; Gelderblom H; Dirix LY; Paridaens R; Bartlett JMS; Nortier JWR; van de Velde CJH;
Ann Oncol; 2012 Dec; 23(12):3091-3097. PubMed ID: 22865782
[TBL] [Abstract][Full Text] [Related]
9. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial.
Barnadas A; Gil M; González S; Tusquets I; Muñoz M; Arcusa A; Prieto L; Margelí-Vila M; Moreno A
Br J Cancer; 2009 Feb; 100(3):442-9. PubMed ID: 19156139
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.
Tsoi DT; Inoue M; Kelly CM; Verma S; Pritchard KI
Oncologist; 2010; 15(5):457-65. PubMed ID: 20421264
[TBL] [Abstract][Full Text] [Related]
11. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial.
Bartlett JM; Brookes CL; Piper T; van de Velde CJ; Stocken D; Lyttle N; Hasenburg A; Quintayo MA; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix LY; Seynaeve C; Rea DW
Br J Cancer; 2013 Oct; 109(9):2453-61. PubMed ID: 24091623
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer.
Hashemi-Meshkini A; Keshavarz K; Gharibnaseri Z; Kheirandish M; Kebriaeezadeh A; Nikfar S; Abdollahi M
Arch Med Sci; 2013 Jun; 9(3):472-8. PubMed ID: 23847669
[TBL] [Abstract][Full Text] [Related]
13. Update on breast cancer risk prediction and prevention.
Sestak I; Cuzick J
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):92-7. PubMed ID: 25517358
[TBL] [Abstract][Full Text] [Related]
14. A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735.
Bernard LM; Verma S; Thompson MF; Chan BC; Mittmann N; Asma L; Jones SE
Curr Oncol; 2011 Apr; 18(2):67-75. PubMed ID: 21505597
[TBL] [Abstract][Full Text] [Related]
15. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).
Wong WB; Ramsey SD; Barlow WE; Garrison LP; Veenstra DL
Contemp Clin Trials; 2012 Nov; 33(6):1117-23. PubMed ID: 22981891
[TBL] [Abstract][Full Text] [Related]
16. Optimal breast cancer risk reduction policies tailored to personal risk level.
Ergun MA; Hajjar A; Alagoz O; Rampurwala M
Health Care Manag Sci; 2022 Sep; 25(3):363-388. PubMed ID: 35687269
[TBL] [Abstract][Full Text] [Related]
17. The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?
Younis T; Groom A
Curr Oncol; 2015 Apr; 22(2):77-9. PubMed ID: 25908904
[No Abstract] [Full Text] [Related]
18. Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.
Kittaneh M; Glück S
Breast Cancer (Auckl); 2011; 5():209-26. PubMed ID: 22084574
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
